Media Citizen's Blog

Just another weblog

Posts Tagged ‘ImmuneRegen

Anti-Radiation Drugs

leave a comment »

                                Will this make for ‘winnable’ nuclear war?


On November 14, 2007, BARDA held its “Industry Day”, listing these four corporate presenters and their radiopharmaceuticals:

ImmuneRegen; Hal Siegel presenting ‘Homspera’; IR Biosciences also has the product Radilex; “The Company will..address the role that Radilex can play in mitigating the effects of a ‘dirty bomb.’…After multiple delays, the RFP was cancelled on March 7, 2007 because none of the companies that submitted to the RFP met the government’s requirements. ImmuneRegen’s Radilex was not submitted in response to the initial RFP in early 2006 as insufficient data had been collected. While this leaves the Nation without a next-generation candidate radioprotective compound for procurement into the Strategic National Stockpile, it highlights the possibility that ImmuneRegen’s Radilex, an 11-amino acid, non-steroid, peptide analog of the endogenous neuromodulator Substance P, could provide a safe and effective candidate once additional data is collected. Animal studies have shown Radilex to protect mice from lethal gamma irradiation, as well as a number of bacterial and viral infections.”


Exponential Biotherapies; Zsolt Harsanyi presenting a radioprotect peptide for acute exposure. Dr. Harsanyi is the founder of DynPort Vaccine, former CEO/pres. of Porton International plc, and current director of Emergent BioSolutions (BioPort), makers of the only licensed anthrax vaccine BioThrax. Hasanyi is also chairman of the American Hungarian Foundation, furthering the biotech interests of George Soros,, and has been a Bio-terror consultant to the US gov’t since the the 1980s.  Jerome Hauer (below) also became a director of Emergent BioSolutions at the same time as Dr. Harsanyi in the summer of 2004.


RxBio Inc.; presenting a novel drug RX100 ;


Cleveland BioLabs Inc.; Alan Wolfman presenting CBLB502; >>Board of Directors                    


La Jolla, California –  BIOTECH

Hollis-Eden Pharmaceuticals Hollis-Eden is spending millions to develop its ‘radioprotection’ drug candidate NEUMUNE …”Hollis-Eden is collaborating in its radiation protection program with The Henry M. Jackson Foundation for the Advancement of Military Medicine and the Armed Forces Radiobiology Research Institute (AFRRI), an agency within the U.S. Department of Defense specializing in research on and development of countermeasures to radiation injury.”

…”Also in radiation and chemotherapy protection, Hollis-Eden has begun profiling for near-term development a series of compounds that have the potential to protect against DNA mutations believed to be an underlying cause of the increased incidence of cancer that has been demonstrated as a late effect of radiation injury and is also associated with secondary cancers following chemotherapy. The lead compound in the series being developed for radiation protection is PHOSPHONOL(TM), which, like NEUMUNE, may be eligible for approval under the FDA’s new animal efficacy rule in this indication. Hollis-Eden obtained the rights to this series of compounds in the first quarter of 2004 through the acquisition of Congressional Pharmaceutical Corporation.” Jerome Hauer, a leading figure in the events of September 11, became a director of Hollis-Eden Pharmaceuticals in 2004. Dwight Stickney directed radiation research for Scripps and handed out the Radiation Study research grants for the NIH. Stickney also held positions with the CDC and Burroughs Wellcome

[posted at]


“Hollis-Eden Pharmaceuticals, Inc. is a development-stage pharmaceutical company based in San Diego, California, working to become the world leader in the development of a new class of investigational drugs known as Immune Regulating Hormones (IRHs). The goal of IRH therapy is to direct, through controlling gene expression, the production of key cytokines and enzymes that re-regulate immune and metabolic functions”…

“Hollis-Eden’s political and scientific quest to get a potential BioShield drug approved and purchased by the federal government could serve as a road map for biotechs with similar ambitions. For Hollis-Eden, the road to Washington began at Ground Zero. Just days after the terrorist attack on the World Trade Center in September 2001, Hollis said he received a telephone call from Navy Adm. James Zimble, a top military health official.” 

Neumune –  for the treatment of Acute Radiation Syndrome (ARS) which is “a potentially lethal condition caused by high-dose radiation exposure that might result from a nuclear or radiological terrorist attack or from an accident at a nuclear facility.” Permission for Phase I trials on humans was registered in May of 2005, according to the statement of CEO Richard Hollis, formerly of Genentech. Neumune was deemed “technically unacceptable” by the Department of Health and Human Services according to this March 2008 article. CEO Michael Wilhelm from competitor company ImmuneRegen BioSciences of Scottsdale Arizona with the Radilex product, suggests a lack of data may have caused HHS to cancel its contract with Hollis-Eden. The article mentions a ‘radioprotectant molecule’ is also in development by Cleveland BioLabs Inc.


Who is Jerome Hauer; the first director of the New York City (Mayor Giuliani’s) Office of Emergency Management, a position created in 1996, 3 years after the first WTC bombing. During his tenure, Hauer organized the construction of the WTC7 Command post, begun in June of 1998, and directed the pesticide spraying for St. Louis encephalitis and/or West Nile Virus He’s considered the nation’s leading expert on bioterrorism, and has himself contributed to work on bioweapons, although his Hollis-Eden biography lists his academic field as psychology and history (at NYU) with a Master’s degree in Public Health from Johns Hopkins.

Hauer was in the TV studio to lay blame on Osama Bin Ladin in the minutes after the WTC attack    JEROME HAUER: Director of Mayor RUDOLPH GIULIANI‘s Office of Emergency Management between February 1996 and March 2000 (as such he was primary in building the City’s Emergency Command Center on the 23rd floor of World Trade Center Building 7 and in warning about emergence of the West Nile Virus one year before it appeared in New York City); Managing Director of Kroll, Inc. [WTC security] on 9/11/01 (when he advised Dan Rather of CBS that demolition had not brought down a Twin Tower and that the day’s attacks bore “the fingerprints of Osama bin Laden”; Senior Adviser to U.S. Secretary of Health and Human Services for National Security and Emergency Management between June 2001 and November 2003; coordinator of the National Institute of Health’s investigation of anthrax deaths in Fall of 2001, deaths that came from the Ames strain of anthrax thought to be available only at the U.S. Army Medical Research Institute of Infectious Diseases at Fort Detrick, Maryland, the N.I.H. investigation producing no suspects named by Jerome Hauer except Osama bin Laden and al Queda; current Director on the Boards of the companies Emergent Biosolutions and San Diego-based Hollis Eden Pharmaceuticals.”


MAXY-G34, developed by Maxygen Inc., for treating ARS neutropenia, licensed to Cangene  May 2009
About ARS – ARS is an acute and potentially life threatening illness caused by exposure to ionizing radiation over a very short period of time. About Neutropenia – Neutropenia is a severe decrease in neutrophil cell counts in the blood. Neutropenia is a common side effect of chemotherapeutic treatments for many forms of cancer, including breast cancer, lung cancer, lymphomas and leukemias. Neutropenic patients are at increased risk of contracting bacterial infections, some of which can be life threatening. Further, and most importantly, neutropenic patients may receive reduced or delayed chemotherapy treatment, which can result in cancer progression. Severe neutropenia is also an early, potentially life threatening feature of the hematopoietic syndrome of ARS (h-ARS).”

Cangene has..submitted a bid to develop a therapeutic for treating ARS under a request for proposal (RFP) issued March 13, 2009 by the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services. Cangene’s submission under the RFP specifies its intention to develop MAXY-G34 for the ARS indication.”


Cangene news: